Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Abatacept for Prevention of Recurrence in IgG4-Related Disease
2022-003916-10Phase 2Active
- Sponsor
- IRCCS Ospedale San Raffaele
- Start
- Feb 2023
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised trial in IgG4-related disease (IgG4-RD) comparing Abatacept with Placebo (2 arms). Primary endpoint: Reduction of disease recurrence at 48 weeks. Started Feb 2023; status: active.
02
Drugs
abatacept
03
Conditions
IgG4-related disease (IgG4-RD)
Beyond the preview
Go deeper on 2022-003916-10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-003916-10.